Larimar Therapeutics, Inc. (LRMR) has released an update.
On February 12, 2024, a company announced the successful completion of a significant Phase 2 trial for nomlabofusp, a treatment for Friedreich’s ataxia, through a press release and updated investors with presentations on their website. These materials are expected to be used in upcoming discussions with investors and analysts to showcase progress and potential.
For further insights into LRMR stock, check out TipRanks’ Stock Analysis page.
